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Abstract
Introduction Previously, in a 40-week, randomised,
double-blind, placebo-controlled core study comprising
three phases (9-week dose confirmation, 5-week open-label
dose optimisation and 6-month maintenance of effect) in
adults with attention-deficit/hyperactivity disorder
(ADHD), methylphenidate modified-release long-acting
formulation (MPH-LA) at 40–80 mg/day controlled
ADHD symptoms as well as decreased functional impair-
ment with a good tolerability profile (NCT01259492).
Here, we report the long-term efficacy and safety from a
26-week, open-label extension phase of the same study
(NCT01338818).
Methods Patients in the extension study (n = 298) initi-
ated treatment with MPH-LA (20 mg/day), up-titrated in
increments of 20 mg/week to reach individual patient’s
daily optimal dose of 40–80 mg. Adverse events (AEs) and
serious adverse events (SAEs) were reported at the end of
extension study for events monitored from (1) maintenance
of effect phase baseline (core study; 12 months) and (2)
extension study baseline (6 months). Mean changes in
DSM-IV ADHD Rating Scale (DSM-IV ADHD RS) and
Sheehan Disability Scale (SDS) total scores are reported
for both the timelines. Efficacy was also evaluated using
clinician-rated instruments, namely Clinical Global
Impression-Improvement Scale (CGI-I) and Clinical Glo-
bal Impression-Severity Scale (CGI-S).
Results No unexpected AEs were reported in the exten-
sion study. Incidence of SAEs reported during 6 months
and 12 months were similar (0.7 %), and no deaths were
reported. No SAEs were considered attributable to the drug
at the end of 12 months. There were no reports of patients
with QT, QTcB or QTcF[500 ms. The mean improvement
in DSM-IV ADHD RS and SDS total scores at the end of
12 months were 0.9 and 1.4 points, respectively; and at the
end of 6 months were 7.2 and 4.8, respectively. The pro-
portion of patients with improvement in CGI-S scale was
31.4 % and 52.1 % at the end of 12 and 6 months,
respectively. Overall, 69.4 % of patients showed clinical
improvement in CGI-I scale at the end of 6 months.
Conclusions In adult patients with ADHD, use of MPH-
LA up to 1 year continued to be well tolerated while
maintaining the clinical efficacy.
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Key Points
No unexpected adverse events or serious adverse
events were observed in adult patients with attention-
deficit hyperactivity disorder treated with
methylphenidate modified-release long-acting
formulation over a period of 1 year.
No new or unexpected results were observed in these
patients with regards to the laboratory findings, vital
signs, or ECG.
Patients maintained symptomatic improvement and a
reduction in functional impairment over a period of
1 year.
1 Introduction
Attention-deficit hyperactivity disorder (ADHD) is a
common neurobehavioural, disabling developmental dis-
order with strong heritability and an estimated global
prevalence of approximately 5 % in children and adoles-
cents [1]. Until the publication of the Diagnostic and
Statistical Manual of Mental Disorders III revised edition
(DSM-III-R), ADHD was considered to be applicable only
to children [2]. Long-term follow-up studies have revealed
that ADHD persists during adulthood. In spite of remission,
approximately 50–60 % of childhood-onset ADHD persists
into adolescence and adulthood [3, 4]. Methylphenidate
remains one of the most commonly prescribed medications
for the treatment of ADHD in adults because of availability
of efficacy and safety data [5–16].
Results from previous studies have indicated long-term
efficacy and a good tolerability profile for osmotic-release
methylphenidate hydrochloride long-acting (OROS-MPH)
in flexible dose range in management of ADHD in adults
[17, 18]. Methylphenidate modified-release long-acting
formulation (MPH-LA; Ritalin-LA, Novartis Pharma
AG) is currently approved for the treatment of ADHD in
children aged 6 years and above in several European
countries [19–21]. A 40-week, double-blind, randomised,
placebo-controlled, multicentre core study was conducted
to evaluate the efficacy and safety of MPH-LA in adults
with ADHD [22]. The study reported that MPH-LA was
safe and effective in the treatment of ADHD in adults, in a
dose range of 40–80 mg/day, and this effect was main-
tained for at least 6 months. Statistically significant
improvement in both DSM-IV ADHD Rating Scale (DSM-
IV ADHD RS) and Sheehan Disability Scale (SDS) was
observed with MPH-LA treatment, and the safety profile
was comparable to that of treatment in children.
Long-term safety and efficacy of MPH-LA in adults
with ADHD is not yet reported. In order to address this, a
6-month, open-label, flexible-dose, multicentre extension
study to the above described 40-week core study was
conducted. Here we report the long-term (1 year; last phase
of core study ? extension study) efficacy and safety of
MPH-LA in adults with ADHD.
2 Methods
The current study concentrates on the last phase of the core
study (maintenance of effect phase) and the succeeding
extension phase conducted at 48 centres in six countries.
The core study was conducted between 24 November 2010
and 7 August 2012, and the extension study was conducted
between 12 April 2011 and 5 February 2013. The study
protocol of the core and extension trials was designed in
accordance with the guidelines on studies in ADHD [23].
Written informed consents were provided by all the
enrolled patients. The study protocol and all the amend-
ments were approved by the Institutional Review Board or
Independent Ethics Committee (core: NCT01259492;
extension: NCT01338818). The study was conducted in
accordance with the ethical principles of the Declaration of
Helsinki.
2.1 Study Design
The study design of the core study is described elsewhere
[22]. Briefly, this was a 6-month, multicentre, open-label
extension of a 40-week, double-blind, randomised, pla-
cebo-controlled core study (NCT01259492) that comprised
three phases: 9-week dose confirmation phase, 5-week
open-label dose optimisation phase and 6-month mainte-
nance of effect phase (Fig. 1a). The 6-month maintenance
of effect phase was a double-blind, randomised, placebo-
controlled, withdrawal period to evaluate the maintenance
effect of MPH-LA in adults with ADHD.
Eligible patients entering the extension study
(NCT01338818) were initiated on treatment with MPH-LA
20 mg and up-titrated to their optimal doses (dose at which
there was an optimal balance between control of symptoms
and adverse effects) of 40, 60 or 80 mg/day in increments
of 20 mg/week for the first 3 weeks of the extension study
(i.e. week 41–43). This re-titration was necessary to
accommodate patients who entered the extension study
from the placebo arm of the maintenance of effect phase of
the core study. The investigator had the flexibility to
readjust the doses as necessary (between weeks 44 and 66)
as long as the dose remained in the range of MPH-LA
40–80 mg/day (Fig. 1b).
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2.2 Study Participants
The study population consisted of ADHD patients
(18–60 years) with confirmed childhood onset according to
DSM-IV diagnostic criteria [24]. Inclusion criteria for the
core study have been previously described [22]. Adult
ADHD patients entering the extension study had either
completed the 6-month maintenance of effect phase of the
core study or discontinued from the maintenance of effect
phase due to lack of therapeutic effect (defined as C30 %
worsening from the maintenance of effect phase baseline
and\30 % remaining improvement from the beginning of
the core study, using DSM-IV ADHD RS).
A total of 298 patients entered the extension study and
received treatment with MPH-LA (Ritalin LA, Novartis
Pharma AG: a racemic mixture of d- and l-threomethyl-
phenidate modified-release hard capsules). Of these, 156
patients were treatment responders (MPH-LA, n = 132;
placebo, n = 24) and 91 patients were treatment non-
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Fig. 1 Study design of the core and extension study (a) adapted from core study manuscript [22]. MPH-LA methylphenidate modified-release
long-acting formulation
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maintenance of effect phase. Treatment non-responders
were defined as patients who fulfilled both the lack of
therapeutic effect criteria in the maintenance of effect
phase of the core study. Of the enrolled patients, 51
patients (MPH-LA, n = 38; placebo, n = 13) had discon-
tinued in the maintenance of effect phase of the core study
prior to the implementation of an amendment to the
inclusion criteria for the extension study protocol (treat-
ment non-responders were required to fulfil both the lack of
therapeutic effect criteria). These 51 patients were classi-
fied as ‘missing treatment non-responders’.
Details of exclusion criteria for the core study are
provided elsewhere [22]. In summary, for the extension
study, patients who had developed or showed evidence of
psychiatric, cardiovascular, cerebrovascular, respiratory,
hepatic, gastrointestinal, renal, haematology or neoplastic
disorders during the course of the core study were
excluded from the extension study. In addition, other
exclusion criteria included pregnancy, seizures, glaucoma,
hyperthyroidism, pheochromocytoma and Tourette’s syn-
drome or a family history of Tourette’s syndrome.
Patients with positive urine drug test or abnormal elec-
trocardiogram at the end of the core study or premature
discontinuation visit were also excluded from the study.
Patients were not allowed to take rescue medication or
psychotropic drugs. Patients undergoing psychological or
behavioural therapies for treatment of ADHD should have
discontinued them at least 1 month prior to the screening
visit. Psychological or behavioural treatments for reasons
other than ADHD had to be discontinued 3 months prior
to entering the study or kept stable with the same thera-
pist during the whole study.
2.3 Safety Assessments
The primary objective of the extension study was to assess
the long-term safety of MPH-LA in adults with ADHD.
Safety-related events were monitored in terms of adverse
events (AEs) and serious adverse events (SAEs), and their
severity and relation to the study drug were assessed. In
addition, physical examination, changes in vital parameters
such as blood pressure, pulse rate and haematological
parameters, clinical chemistry and electrocardiogram were
also monitored.
Cumulative safety data for 12 months were collected
and analysed from the combined period of the maintenance
of effect phase of the core study and the extension study.
Safety data for 6 months were collected from the extension
study. Safety data have been presented from two different
baselines: (1) baseline of the maintenance of effect phase
until the end of the extension study (12 months’ data); (2)
baseline of the extension phase to end of the extension
study (6 months’ data).
2.4 Efficacy Assessments
The secondary objective of the study was to evaluate the
long-term efficacy of MPH-LA in adults with ADHD
(assessments from the maintenance of effect phase baseline
and the extension baseline were recorded). Efficacy was
primarily assessed using the DSM-IV ADHD RS and the
SDS. DSM-IV ADHD RS is a clinician-rated instrument
for assessing the severity of ADHD symptoms; it consists
of 18 items directly adapted from the ADHD symptom list
according to the DSM-IV [25]. SDS consists of a five-item,
self-rated questionnaire that measures the extent to which a
patient’s disability due to an illness or health problem (e.g.,
anxiety disorder, painful conditions, ADHD, depression,
etc.) interferes with work/school, social life/leisure activi-
ties, and family life/home responsibilities [26].
Secondary efficacy assessments were performed using
clinician-rated instruments, namely the Clinical Global
Impression-Improvement Scale (CGI-I) and the Clinical
Global Impression-Severity Scale (CGI-S). The CGI-I is
designed to assess the overall change of illness compared
with baseline whereas the CGI-S is designed to assess the
patient’s current illness state [27]. The proportion of
patients with improvement in the CGI-I and CGI-S scales
are reported.
A summary of individual efficacy scales, their sub-
scores, assessment time points, scoring criteria, assessment
baselines and the improvement criteria are provided in
Table 1.
2.5 Statistical Analysis
The study sample size was calculated to ensure exposure of
C300 patients for 6 months and C100 patients for
12 months to get the combined exposure data from core
and extension studies in accordance with the International
Conference on Harmonisation (ICH) guidelines [28] to
assess the long-term safety and efficacy of the treatment
with MPH-LA.
The All Extension Patients (AEP) analysis set included
all patients who had entered the open-label extension study
and received at least one dose of MPH-LA. This analysis
set was used for all efficacy and safety analyses (Table 2).
Safety analysis of AEP:
• for 12 months was conducted based on treatment given
in the maintenance of effect phase (MPH-LA or
placebo)
• for 6 months was based on mean daily dose given in the
extension study (MPH-LA mean daily dose of B40 mg
or [40–60 mg or [60 mg).
Efficacy in AEP (for 12 months and 6 months) was
evaluated based on:
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Pt rates extent to which work, social
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impaired on a 10-point VAS. Scores
C5 on any of these scales are
associated with significant functional
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to measure global functional
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A decrease in SDS score (total and sub-
scores) at the end of the study from
the BLs indicates improvement in
functional impairmentb
CGI-I NA 41, 42, 43,
46, 54, 62,
and 66
Clinician rated to assess overall change
of illness relative to BL
Consists of 7 ratings, ranging from 1




Low score between 1 and 3 reflects
greater improvement; score of 4
shows ‘no change’; scores [4
correspond to worsening in ADHD
symptoms
CGI-S NA 66 Clinician rated to assess the pt’s current
illness state
Consists of 7 ratings that range from 1
(normal, not at all ill) to 7 (among the







A decrease in CGI-S score at the end of
the study from the BLs indicates
improvement in ADHD symptoms
BL baseline, CGI-I Clinical Global Impression-Improvement Scale, CGI-S Clinical Global Impression-Severity Scale, DSM IV ADHD RS
Diagnostic and Statistical Manual of Mental Disorders IV attention-deficit hyperactivity disorder rating scale, NA not applicable, pts patients,
SDS Sheehan Disability Scale, VAS visual analogue scale
a Total DSM-IV ADHD RS score is a sum of Inattention and Hyperactivity/Impulsivity sub-scores
b In the current manuscript, the change is indicated as mean improvement
c Total SDS score is a sum of work, social life and family life disability sub-scores
Table 2 All extension patients analysis set
Analysis data sets ‘All extension patients’ analysis set
MPH-LA mean daily dose in extension
study
Tx received in maintenance of effect phase of
core study
Total number of pts treated
B40 mg [40–60 mg [60 mg Placebo MPH-LA
Efficacy analysis – – – 82 216 298
Safety analysisa 85 104 109 – – 298
Safety analysisb – – – 82 216 298
MPH-LA methylphenidate modified-release long-acting formulation, pts patients, tx treatment
a During extension study
b During maintenance of effect phase of core study and extension study
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• treatment given in the maintenance of effect phase of
the core study (MPH-LA or placebo).
For both safety and efficacy parameters, data were
summarised using descriptive statistics (n, mean, standard
deviation, minimum, median, maximum) for continuous
variables and using contingency tables (n, %) for discrete
variables.
3 Results
3.1 Patient Disposition and Baseline Demographics
Patient disposition for the core study was described in the
core study manuscript [22]. Overall, 298 patients aged
18–60 years with ADHD who had either completed the
core study or discontinued from the maintenance of effect
phase of the core study (due to lack of therapeutic effect)
entered the extension study. Of these, 262 (87.9 %) com-
pleted the extension study and 36 (12.1 %) discontinued
from the study. The most common reasons for discontin-
uation were withdrawal of consent by the subjects (3.7 %,
n = 11) followed by discontinuation due to AEs (2.7 %,
n = 8) (Fig. 2).
Demographics and baseline characteristics are represented
based on treatment (MPH-LA or placebo) received during the
maintenance of effect phase and were similar for both MPH-
LA and placebo patients (Table 3). Among the patients
enrolled in the extension study, 160 (53.7 %) were males, and
the mean age in the study was 36.3 ± 11.40 years. Most of the
patients (n = 272, 91.3 %) were Caucasians.
3.2 Duration of Exposure to Methylphenidate
Modified-Release Long-Acting Formulation
(MPH-LA)
Of the 298 patients in the extension study, 85 received a
mean daily dose of MPH-LA B40 mg; 104 patients
received [40–60 mg, and 109 patients received [60 mg
during the extension study. The overall mean duration of
exposure for MPH-LA was 170.5 days in the AEP group,
and the mean duration of exposure to the MPH-LA was
155.2, 172.9, and 180.0 days for the B40 mg,[40–60 mg,
and [60 mg mean daily dose groups, respectively. A total
of 125 patients were treated with MPH-LA continuously
for the entire duration of 12 months (maintenance of effect
phase and extension phase). A total of 136 patients were
continuously exposed to MPH-LA for the duration of
[365 days, and 354 patients were continuously exposed to
MPH-LA for the duration of [180 days throughout the
entire core and extension study. The continuous exposure
to MPH-LA was compliant with the ICH guidelines [28] to
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3.3 Safety of MPH-LA Over a Continuous Treatment
Exposure of up to 12 Months
Overall incidence of AEs from the maintenance of effect
phase baseline of the core study to end of extension study
was 80.5 % (n = 240) in the AEP set. AEs described here
are based on treatment (placebo or MPH-LA) received in
the maintenance of effect phase. Overall, the incidence of
AEs was comparable between patients receiving placebo
(79.3 %, n = 65) and those receiving MPH-LA (81.0 %,
n = 175) during the maintenance of effect phase of the
core study. Incidence of nasopharyngitis, nausea, upper
respiratory tract infection and fatigue was higher (C5 %) in
patients receiving MPH-LA, while the incidence of head-
ache, decreased appetite, dry mouth, diarrhoea, back pain,
anxiety, gastroenteritis, oropharyngeal pain, influenza and
tachycardia was higher (C5 %) in patients receiving pla-
cebo. SAEs were observed only in about 0.7 % (n = 2) of
AEPs from the maintenance of effect phase baseline to the
end of the extension study. Both SAEs were observed in
the MPH-LA group. One patient reported exostosis of
moderate severity on extension day 146, and another
patient reported pancreatitis and non-Hodgkin’s lymphoma
(pre-existing before enrolment into this study) (Table 4).
Neither of these SAEs was suspected to be related to the
study medication. No clinically significant observations
were noted in haematological or clinical chemistry
parameters in the extension study. A single patient reported
clinically notable low systolic blood pressure, and five
patients (1.7 %) reported clinically notable changes in
diastolic blood pressure (four patients with high, one
patient with low). Six patients (2.0 %) were reported to
have a notable change in heart rate (three patients each
with a high and a low rate). Clinically notable changes in
weight were recorded in 29 (9.9 %) patients in the AEP.
None of the patients had a QT, QTcB or QTcF C500 ms.
Table 3 Demographic and baseline characteristics of all extension patients based on treatment received in the maintenance of effect phase
Variable Treatment received in the maintenance of effect phase All extension patients (N = 298)
MPH-LA (N = 216) Placebo (N = 82)
Age (years) 36.6 ± 11.39 35.4 ± 11.45 36.3 ± 11.40
Age group (years)
18–30 73 (33.8) 34 (41.5) 107 (35.9)
31–40 47 (21.8) 15 (18.3) 62 (20.8)
41–50 74 (34.3) 25 (30.5) 99 (33.2)
51–60 22 (10.2) 8 (9.8) 30 (10.1)
Sex
Male 115 (53.2) 45 (54.9) 160 (53.7)
Female 101 (46.8) 37 (45.1) 138 (46.3)
Race
Caucasian 200 (92.6) 72 (87.8) 272 (91.3)
Black 3 (1.4) 4 (4.9) 7 (2.3)
Asian 2 (0.9) 1 (1.2) 3 (1.0)
Native American 1 (0.5) 0 1 (0.3)
Others 10 (4.6) 5 (6.1) 15 (5.0)
Ethnicity
Hispanic 19 (8.8) 6 (7.3) 25 (8.4)
Chinese 0 1 (1.2) 1 (0.3)
Indian (Indian subcontinent) 2 (0.9) 0 2 (0.7)
Japanese 1 (0.5) 0 1 (0.3)
Mixed ethnicity 1 (0.5) 0 1 (0.3)
Others 193 (89.4) 75 (91.5) 268 (89.9)
Height (cm) 173.6 ± 9.35 173.5 ± 8.78 173.6 ± 9.18
Weight (kg) 75.7 ± 15.69 78.3 ± 15.50 76.4 ± 15.65
BMI (kg/m2) 25.0 ± 3.88 25.9 ± 4.40 25.2 ± 4.04
Current smoker 59 (27.3) 24 (29.3) 83 (27.9)
All data are presented as mean ± SD or n (%)
BMI body mass index, MPH-LA methylphenidate modified-release long-acting formulation, SD standard deviation
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There were minor changes from maintenance of effect
baseline in the mean QTc intervals (0.7 ms for QTcB and
1.2 ms for QTcF) in the AEP. There were no clinically
meaningful dose-related differences observed between the
MPH-LA mean daily doses.
3.4 Safety Profile of MPH-LA Over a Continuous
Treatment Exposure of up to 6 Months
in the Extension Study
The overall incidence of AEs occurring in the extension
study was 69.8 % (n = 208). Incidence of AEs was com-
parable between MPH-LA mean daily dosage groups
(69.4 %, n = 59; 75.0 %, n = 78; and 65.1 %, n = 71 in
the B40, [40–60 and [60 mg dosage groups, respec-
tively). The most common AE was nasopharyngitis, with
an overall incidence of 19.1 % (n = 57). Incidence of
nasopharyngitis was higher in the [40–60 mg group
(27.9 %) compared with that in the B40 and [60 mg
groups (17.6 % and 11.9 %, respectively). Headache,
decreased appetite, dry mouth and nausea were the other
AEs reported, with a frequency of more than 5 % among
all patients. No deaths were reported in the study. Two
patients receiving a dosage of[60 mg/day reported SAEs;
one patient reported exostosis, and the other patient
reported pancreatitis and non-Hodgkin’s lymphoma. The
exostosis reported was of moderate severity, and the patient
recovered with non-drug therapy and continued the study.
The patient with pancreatitis and non-Hodgkin’s lym-
phoma received concomitant medication, with temporary
discontinuation of the study drug, and then completed the
study. Neither of the SAEs was suspected to be related to
the study drug (Table 5).
Three of the extension patients had clinically notable
changes in blood pressure: two patients ([60 mg MPH- LA
mean daily dose) with high and one patient ([40–60 mg
MPH-LA mean daily dose) with low diastolic blood pres-
sure. There were no reports of clinically notable changes in
systolic blood pressure. Three patients (1.0 %) receiving a
mean daily dose of [60 mg MPH-LA were reported to
have a notable increase in heart rate, and 20 patients
(6.9 %) showed a clinically notable decrease in weight.
None of the patients had a QT, QTcB or QTcF C500 ms
during the extension phase. There were minor changes
from extension baseline in the mean QTc intervals in the
AEP (2.4 ms for QTcB and 1.0 ms for QTcF). Patients
with mean daily dose of B40 mg showed minimal changes
in QTcB (-0.6 ms) and QTcF (0.4 ms) intervals during the
extension study.
Table 4 Safety of methylphenidate modified-release long-acting formulation over a continuous treatment of up to 12 months
MPH-LA in maintenance of effect phase
(N = 216)




Total AEs 175 (81.0) 65 (79.3) 240 (80.5)
Total SAEs 2 (0.9) 0 (0.0) 2 (0.7)
Death 0 0 0
AEs by preferred term (C5 % for any group)
Nasopharyngitis 59 (27.3) 20 (24.4) 79 (26.5)
Headache 41 (19.0) 21 (25.6) 62 (20.8)
Decreased
appetite
15 (6.9) 11 (13.4) 26 (8.7)
Dry mouth 15 (6.9) 9 (11.0) 24 (8.1)
Nausea 15 (6.9) 3 (3.7) 18 (6.0)
URTI 13 (6.0) 4 (4.9) 17 (5.7)
Diarrhoea 9 (4.2) 6 (7.3) 15 (5.0)
Back pain 9 (4.2) 5 (6.1) 14 (4.7)
Fatigue 11 (5.1) 3 (3.7) 14 (4.7)
Anxiety 7 (3.2) 6 (7.3) 13 (4.4)
Gastroenteritis 8 (3.7) 5 (6.1) 13 (4.4)
Oropharyngeal
pain
6 (2.8) 5 (6.1) 11 (3.7)
Tachycardia 5 (2.3) 6 (7.3) 11 (3.7)
Influenza 3 (1.4) 5 (6.1) 8 (2.7)
All data are presented as n (%)
AE adverse event, SAE serious adverse event, URTI upper respiratory tract infection
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3.5 Efficacy of MPH-LA Over a Continuous Treatment
Period of up to 12 Months
The mean improvement in total score of DSM-IV ADHD
RS from the maintenance of effect phase baseline to the end
of the extension study was 0.9 (Fig. 3). The mean
improvement in SDS total score from the maintenance of
effect phase baseline to the end of the extension study was
1.4 (Fig. 3). A total of 91 (31.4 %) patients showed
improvement in CGI-S score from the maintenance of
effect phase baseline to the end of the extension study









































Fig. 3 Mean improvement in DSM-IV ADHD RS and SDS total
scores from maintenance of effect baseline (12 months data). DSM-IV
ADHD RS Diagnostic and Statistical Manual of Mental Disorders IV
attention-deficit hyperactivity disorder rating scale, MPH-LA meth-
ylphenidate modified-release long-acting formulation, SDS Sheehan
Disability Scale
Table 5 Safety of methylphenidate modified-release long-acting formulation over a continuous treatment of up to 6 months
MPH-LA mean daily
dose B40 mg (N = 85)
MPH-LA mean daily
dose [40–60 mg (N = 104)
MPH-LA mean daily
dose [60 mg (N = 109)
All extension
pts (N = 298)
Total AEs 59 (69.4) 78 (75.0) 71 (65.1) 208 (69.8)
Total SAEs 0 (0.0) 0 (0.0) 2 (1.8) 2 (0.7)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AEs by preferred term (C5 % for any group)
Nasopharyngitis 15 (17.6) 29 (27.9) 13 (11.9) 57 (19.1)
Headache 15 (17.6) 12 (11.5) 15 (13.8) 42 (14.1)
Decreased appetite 4 (4.7) 12 (11.5) 7 (6.4) 23 (7.7)
Dry mouth 4 (4.7) 12 (11.5) 4 (3.7) 20 (6.7)
Nausea 7 (8.2) 4 (3.8) 4 (3.7) 15 (5.0)
URTI 1 (1.2) 4 (3.8) 9 (8.3) 14 (4.7)
Insomnia 2 (2.4) 7 (6.7) 2 (1.8) 11 (3.7)
Sinusitis 2 (2.4) 6 (5.8) 3 (2.8) 11 (3.7)
Gastroenteritis 0 (0.0) 3 (2.9) 7 (6.4) 10 (3.4)
Fatigue 5 (5.9) 3 (2.9) 1 (0.9) 9 (3.0)
All data are presented as n (%)
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Fig. 4 Mean improvement in DSM-IV ADHD RS and SDS total
scores from extension baseline (6 months data). DSM-IV ADHD RS
Diagnostic and Statistical Manual of Mental Disorders IV attention-
deficit hyperactivity disorder rating scale, MPH-LA methylphenidate
modified-release long-acting formulation, SDS Sheehan Disability
Scale
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3.6 Efficacy of MPH-LA over a Continuous Treatment
of up to 6 Months in the Extension Study
The mean improvement in total score of DSM-IV ADHD
RS and SDS from extension baseline to the end of the study
was 7.2 and 4.8, respectively (Fig. 4). Overall, 206
(69.4 %) patients showed improvement in CGI-I rating
(MPH-LA, 141 (65.3 %); Placebo, 65 (80.2 %)), and 151
(52.1 %) patients showed improvement in CGI-S scale
(MPH-LA, 91 (42.9 %); Placebo, 60 (76.9 %)) from the
extension study baseline to the end of the extension study.
4 Discussion
Results of this extension study, combined with the results
of the 6-month maintenance of effect phase of the core
study, showed that MPH-LA at a dose of 40–80 mg/day
administered once daily in adult patients with ADHD is
safe and maintains efficacy up to a period of 1 year. The
overall incidences of AEs reported in the maintenance of
effect phase or the extension phase were comparable
between patients receiving MPH-LA and placebo in the
maintenance of effect phase of the core study, and the
safety profile of MPH-LA did not change with the longer
duration of treatment. No consistent relationship was
observed between the mean daily dose of MPH-LA and the
incidence of AEs. The flexible dosing regimen applied in
the extension study allowed titration of MPH-LA dose,
such that every individual patient received the dose at
which an optimal balance between control of symptoms
and adverse effects was achieved. There were no unex-
pected AEs or SAEs reported in this study. The most
common AEs were nasopharyngitis, headache, nausea,
decreased appetite and dry mouth, which were similar to
those reported in previous studies with other formulations
of MPH both in children and adults with ADHD [13, 29–
31]. These findings will help address the limited data
availability on the long-term safety of MPH in the treat-
ment of adults with ADHD [32].
The proportion of patients receiving MPH-LA who
discontinued the extension study due to AEs was 2.3 %,
which is much lower than the 18.5 % as reported in a
similar 1-year, open-label study on safety of OROS-MPH
(36–108 mg/day) in the treatment of adult ADHD patients
[17] and the 14.7 % in another 6-month, open-label study
on safety and efficacy of dexmethylphenidate extended
release (d-MPH-ER) (20–40 mg/day) [29]. The reason for
a higher proportion of patients discontinuing due to AEs in
these two studies was reported to be dose related, thus
necessitating dose reductions in these patients. We suggest
that the lower incidence of discontinuation related to MPH-
LA in this study can be attributed to the flexible, optimised
titration of MPH-LA daily dose in the open-label extension
study, thus ascertaining an optimal balance between control
of symptoms and AEs.
Overall, only two (0.7 %) patients in the [60 mg dose
group reported SAEs, neither of which were considered to
be related to the study drug. The incidence of SAEs in this
study was lower than that observed in a similar open-label,
dose titration, 1-year flexible dose study (36–108 mg/day
OROS-MPH) that assessed the safety of OROS-MPH. In
that study, 1.5 % of patients reported SAEs, none of which
were considered to be related to the study drug [17]. None
of the patients reported QT, QTcB or QTcF [500 ms.
Overall, the modest change in vital signs and electrocar-
diogram (ECG) parameters in patients treated with MPH is
not considered to be clinically meaningful and is thought to
be consistent with the known effects of stimulant medica-
tions in ADHD [32].
The results of this extension study suggest improvement
in ADHD symptoms and reduction in functional impair-
ment as measured by the DSM-IV ADHD RS, SDS and
CGI scales. Mean improvement in total scores of DSM-IV
ADHD RS and SDS from the maintenance of effect phase
baseline to the end of the extension study were 0.9 and 1.4
points, respectively, confirming that efficacy is maintained
over a period of 1 year. Patients who received MPH-LA in
the maintenance of effect phase and who continued therapy
in the extension study maintained the efficacy as seen in
DSM-IV ADHD RS and SDS total scores at the end of the
extension study. Patients who received placebo compared
with those who received MPH-LA in the maintenance of
effect phase showed marked improvement in their DSM-IV
ADHD RS and SDS total scores after receiving MPH-LA
in the extension study. These results were comparable with
another open-label, 6-month, extension study in which
there was marked clinical improvement in DSM-IV ADHD
RS scores in patients who were switched from placebo to
d-MPH-ER (20–40 mg/day), and the benefit was sustained
in patients who were already receiving MPH [29]. Simi-
larly, mean improvement in the SDS total score (4.8) in this
study was comparable with a 7-week, open-label extension
study in which the improvement in SDS total score was
2.8 ± 6.0 and 4.6 ± 5.8 for patients receiving OROS-
MPH (18–72 mg/day) and placebo, respectively, in the
double-blind period of the study [33].
At the end of the extension study, clinical improvement
in CGI-I rating was noted in 141 (65.3 %) and 65 (80.2 %)
patients treated (in the maintenance of effect phase) with
MPH-LA and placebo, respectively. Although comparison
with other studies is difficult due to patient variability
influencing response, the response rates reported in this
study are similar to those observed in the literature. In a
6-month extension study, 95.1 % of patients maintained on
d-MPH-ER (20–40 mg/day) and 95.0 % of patients who
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switched from placebo to d-MPH-ER showed improvement
in CGI-I [28]. In another 1-year study, 81 % improvement
was observed in CGI-I scores in patients with ADHD
treated with MPH-ER (30–100 mg/day) [31]. Likewise,
improvement in the CGI-S scale observed in 42.9 % and
76.9 % of patients who received MPH-LA and placebo
treatment (in the maintenance of effect phase), respectively,
was similar to that reported in other studies [29, 33].
Overall, the results indicate that MPH-LA at a flexible
dose of 40–80 mg/day maintained long-term efficacy over
a period of 1 year as observed in the improvement of both
ADHD symptoms and functional impairment, as measured
by the DSM-IV ADHD RS, SDS and CGI scales.
5 Strengths and Limitations
The key strength of this study was that dosing in the open-
label extension study was flexible and obtained by titrating
MPH-LA daily dose after ascertaining the optimal balance
between control of symptoms and AEs, which closely
reflects clinical practice. There is also a limitation in the
study design, as it is not a true switch study of patients
receiving MPH-LA or placebo switched to MPH-LA
optimal dose in the extension study, as all the patients had
received MPH-LA before entering the maintenance of
effect phase and a sham response was seen in placebo
patients. Another limitation could be that not all the
patients who finished the study had received MPH-LA
continuously for 1 year, and, in these patients, exposure to
MPH-LA was interrupted. On the other hand, this inter-
rupted exposure could also be considered a strength of the
study and be relevant in terms of ecological validity, since
it may reflect real-life exposure.
6 Conclusion
This study confirms the long-term safety and efficacy of
MPH-LA for treatment of adults with ADHD, which is
comparable to the safety events reported in the core study
and other studies of MPH-LA in children with ADHD. No
new safety event was reported upon long-term exposure to
MPH-LA. The safety and efficacy profile of MPH-LA is
also similar to that of other formulations of MPH used in
the treatment of adults with ADHD.
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